Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Earnings
Outlook Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Dec 18, 2026
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$9.00K
-99.4% on a year earlier
adjusted net loss attributable to common stockholders, Q3 FY2026
$0.09
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Outlook Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Sep 30, 2026 | Dec 18, 2026Expected | – | – | – | – | – |
| Q3 FY2026ended Jun 30, 2026 | Aug 14, 2026before the open | $9.00K | -99.4% | $0.15 | $0.09 | Release |
| Q2 FY2026ended Mar 31, 2026 | May 18, 2026after the close | $128.00K | – | $0.05 | $0.16 | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 17, 2026before the open | -$1.21M | – | -$0.38 | -$0.22 | Release |
| Q4 FY2025ended Sep 30, 2025 | Dec 19, 2025before the open | – | – | – | – | Release |
| Q3 FY2025ended Jun 30, 2025 | Aug 14, 2025after the close | $1.50M | – | – | – | Release |
| Q2 FY2025ended Mar 31, 2025 | May 15, 2025after the close | – | – | $1.50 | $0.40 | Release |
| Q1 FY2025ended Dec 31, 2024 | Feb 14, 2025before the open | – | – | $0.72 | -$0.89 | Release |
| Q4 FY2024ended Sep 30, 2024 | Dec 27, 2024before the open | – | – | – | – | Release |
| Q3 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | – | – | -$0.89 | -$0.83 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 15, 2024after the close | – | – | $8.01 | – | Release |
| Q1 FY2024ended Dec 31, 2023 | Feb 14, 2024after the close | – | – | -$0.04 | – | Release |
| Q4 FY2023ended Sep 30, 2023 | Dec 22, 2023after the close | – | – | – | – | Release |
| Q3 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | – | – | -$0.08 | – | Release |
| Q2 FY2023ended Mar 31, 2023 | May 15, 2023after the close | – | – | -$0.03 | – | Release |
| Q1 FY2023ended Dec 31, 2022 | Feb 14, 2023before the open | – | – | -$0.08 | – | Release |
| Q4 FY2022ended Sep 30, 2022 | Dec 29, 2022before the open | – | – | – | – | Release |
| Q3 FY2022ended Jun 30, 2022 | Aug 10, 2022before the open | – | – | -$0.08 | – | Release |
| Q1 FY2022ended Dec 31, 2021 | Feb 14, 2022after the close | – | – | -$0.08 | – | Release |
| Q4 FY2021ended Sep 30, 2021 | Dec 22, 2021after the close | – | – | – | – | Release |
| Q3 FY2021ended Jun 30, 2021 | Aug 13, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Dec 31, 2020 | Feb 16, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Sep 30, 2020 | Dec 28, 2020after the close | – | – | – | – | Filing |
| Q3 FY2020ended Jun 30, 2020 | Aug 14, 2020before the open | – | – | – | – | Filing |
| Q2 FY2020ended Mar 31, 2020 | May 15, 2020after the close | – | – | – | – | Filing |
| Q1 FY2020ended Dec 31, 2019 | Feb 14, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Outlook Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Outlook Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Outlook Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
- Results
- News
- News
- News
- News
- Results
- News
- News
- Results
See a number that looks wrong?